179 related articles for article (PubMed ID: 24885612)
1. Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.
Guo W; Li H; Zhuang D; Jiao L; Liu S; Li L; Liu Y; Gui T; Jia L; Li J
BMC Infect Dis; 2014 May; 14():237. PubMed ID: 24885612
[TBL] [Abstract][Full Text] [Related]
2. Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.
Guo W; Han J; Zhuang D; Liu S; Liu Y; Li L; Li H; Bao Z; Wang F; Li J
Virol J; 2015 Nov; 12():187. PubMed ID: 26578099
[TBL] [Abstract][Full Text] [Related]
3. Impact of Novel Resistance Profiles in HIV-1 Reverse Transcriptase on Phenotypic Resistance to NVP.
Jiao L; Li H; Li L; Zhuang D; Liu Y; Bao Z; Liu S; Li J
AIDS Res Treat; 2012; 2012():637263. PubMed ID: 22536497
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
Liu J; Yue J; Wu S; Yan Y
Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
[TBL] [Abstract][Full Text] [Related]
5. Identification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF_BC strains.
Huang Y; Li Z; Xing H; Jiao Y; Ouyang Y; Liao L; Jiang S; Armstrong R; Shao Y; Ma L
PLoS One; 2014; 9(4):e93804. PubMed ID: 24743727
[TBL] [Abstract][Full Text] [Related]
6. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
Reuman EC; Rhee SY; Holmes SP; Shafer RW
J Antimicrob Chemother; 2010 Jul; 65(7):1477-85. PubMed ID: 20462946
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism and drug selected mutations of reverse transcriptase gene in 102 HIV-1 infected patients living in China.
Liu L; Lu HZ; Henry M; Tamalet C
J Med Virol; 2007 Oct; 79(10):1593-9. PubMed ID: 17705165
[TBL] [Abstract][Full Text] [Related]
8. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
[TBL] [Abstract][Full Text] [Related]
9. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
[TBL] [Abstract][Full Text] [Related]
10. K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data.
Recordon-Pinson P; Papuchon J; Reigadas S; Deshpande A; Fleury H
PLoS One; 2012; 7(5):e36549. PubMed ID: 22615779
[TBL] [Abstract][Full Text] [Related]
11. Emerging trends of drug-resistant HIV-1 among drug-treated patients in former blood donors in Hubei, China: a three-year surveillance from 2004 to 2006.
Gong J; Wang XQ; Tong X; Shen XH; Yang RG
Virol Sin; 2011 Dec; 26(6):386-92. PubMed ID: 22160938
[TBL] [Abstract][Full Text] [Related]
12. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.
Tolle M; Howard L; Kirk B; Gomila A; Schwarzwald H; Anabwani G
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(4):260-8. PubMed ID: 21972264
[TBL] [Abstract][Full Text] [Related]
13. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.
Brehm JH; Koontz DL; Wallis CL; Shutt KA; Sanne I; Wood R; McIntyre JA; Stevens WS; Sluis-Cremer N; Mellors JW;
Clin Infect Dis; 2012 Sep; 55(5):737-45. PubMed ID: 22618567
[TBL] [Abstract][Full Text] [Related]
14. In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors.
Wu H; Zhang XM; Zhang HJ; Zhang Q; Chen Z; Huang JD; Lee SS; Zheng BJ
AIDS Res Hum Retroviruses; 2015 Feb; 31(2):260-70. PubMed ID: 25482475
[TBL] [Abstract][Full Text] [Related]
15. Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines.
Deshpande A; Jeannot AC; Schrive MH; Wittkop L; Pinson P; Fleury HJ
AIDS Res Hum Retroviruses; 2010 Mar; 26(3):343-50. PubMed ID: 20334569
[TBL] [Abstract][Full Text] [Related]
16. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
17. Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
Chendi BH; Okomo Assoumou MC; Jacobs GB; Yekwa EL; Lyonga E; Mesembe M; Eyoh A; Ikomey GM
BMC Infect Dis; 2019 Feb; 19(1):194. PubMed ID: 30808298
[TBL] [Abstract][Full Text] [Related]
18. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
[TBL] [Abstract][Full Text] [Related]
19. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
[TBL] [Abstract][Full Text] [Related]
20. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
